Fortvita Biologics, a member of the Innovent Group, hosted its first booth at a major global oncology congress at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held October 23–27 at IFEMA Madrid, Spain. During the congress, Innovent presented 12 abstracts, including a Late-Breaking Abstract, featuring several programs from its immuno-oncology (IO) and antibody-drug conjugate (ADC) pipeline.
Fortvita leads global development and commercialization of Innovent’s programs outside China, working alongside partners including Takeda. In oncology, Fortvita is advancing next-generation IO and ADC programs, supported by expertise in protein engineering, structure-based drug design, and multispecific antibody technologies.
Innovent ESMO Presentations
IBI343/TAK-921 (Arcotatug Tavatecan)
Innovent presented results from the registrational Phase 3 G-HOPE-001 study of Arcotatug Tavatecan, an investigational Claudin (CLDN)18.2-targeted ADC, as a Late-Breaking Abstract. The study met both primary endpoints, demonstrating statistically significant overall survival and progression-free survival (PFS) benefits in previously treated, CLDN18.2-positive gastric cancer.
IBI363/TAK-928
Innovent presented data from three Phase 1b clinical studies of IBI363/TAK-928, an investigational PD-1/alpha-biased IL-2 bispecific fusion protein, in first-line non-small cell lung cancer, first-line gastric or gastroesophageal junction adenocarcinoma, and immunotherapy-resistant lung adenocarcinoma. In the randomized study in immunotherapy-resistant lung adenocarcinoma, median PFS was significantly prolonged with IBI363/TAK-928 plus bevacizumab versus docetaxel, with a hazard ratio of 0.40 (p=0.0006).
IBI3001
Innovent presented the first international Phase 1 clinical data for IBI3001, an investigational anti-EGFR/B7H3 bispecific ADC, in a Proffered Paper session. The study was conducted in China, Australia, and the United States in patients with advanced solid tumors. IBI3001 has advanced to the dose-optimization stage of a Phase 1b proof-of-concept study.
IBI354
Innovent presented Phase 2 data for IBI354, an investigational HER2-targeted ADC, in combination with pertuzumab as first-line treatment for HER2-positive advanced breast cancer. Two pivotal Phase 3 studies, HeriCare-Breast01 and HeriCare-Ovarian01, have been initiated.
At the Booth
Fortvita’s booth served as a space for scientific exchange on its investigational oncology programs and clinical studies, including studies with partners. Fortvita thanks the clinicians, researchers, and partners who visited, and the Innovent team for its collaboration throughout the congress.
ABOUT FORTVITA
Fortvita Biologics is a clinical-stage biopharmaceutical company headquartered in the San Francisco Bay Area, with global development and commercial operations capabilities across Asia, Europe, Australia, and the United States. As a member of the Innovent Group, Fortvita draws on Innovent Biologics’ proven discovery, development, and manufacturing capabilities. Its pipeline reflects a strong foundation in oncology that is expanding into cardiovascular and metabolic, autoimmune, and ophthalmic diseases.
Fortvita Biologics seeks strategic partnerships to accelerate the development and global accessibility of therapies for patients worldwide. Learn more about partnering with Fortvita here.
Innovent entered into a license and collaboration agreement with Takeda for co-development and co-commercialization of IBI363 (Takeda R&D code: TAK-928), ex-China rights of Arcotatug Tavatecan (Innovent/Takeda R&D Code: IBI343/TAK-921) and an exclusive option right of IBI3001.
Forward-looking statements
This news release may contain certain forward-looking statements regarding Fortvita Biologics (“Fortvita”) that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Fortvita, are intended to identify certain of such forward-looking statements. Fortvita does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on current beliefs, assumptions, expectations, estimates, projections, and understandings of Fortvita’s management with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Fortvita’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements due to factors including, but not limited to, the timing, progress, and results of clinical trials, regulatory approvals, manufacturing capabilities, competition, and changes in political, economic, legal, and social conditions.
Fortvita, its Directors and employees assume (a) no obligation to correct or update any forward-looking statements contained in this release, and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.
Contact
Media:
pr@fortvitabio.com